Most Favored Nation and the Future of Drug Pricing and Access
The U.S. Most Favored Nation (MFN) policy is moving from debate to enforcement with 60-day deadlines, affecting launch pricing, contracts, and global sequencing. Explore key policy insights and impacts in Herspiegel’s Policy Brief.
jpiatt
Tue, 09/09/2025 – 12:11
Read key insights from Herspiegel experts on how the Most Favored Nation policy is reshaping global pricing strategies and what pharma leaders must do now to stay ahead.
Resource Type
Tue, 09/09/2025 – 08:00
Landing Page Url